Curis (CRIS) Non-Current Debt (2012 - 2020)

Curis' (CRIS) quarterly Non-Current Debt came in at $300000.0 in Q4 2020, down 55.09% on a QoQ basis from $668000.0 in Q3 2020.

Curis (CRIS) Non-Current Debt (2012 - 2020) Analysis & Trends

Curis (CRIS) has 8 years of Non-Current Debt data on file, last reported at $300000.0 in Q4 2020.

Quarterly Non-Current Debt changed N/A year-over-year to $300000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $300000.0 (changed N/A YoY) and the FY2020 annual result came in at $300000.0, changed N/A from the prior year.
Non-Current Debt declined to $300000.0 in Q4 2020, from $668000.0 in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $37.8 million in Q3 2017 to a low of $300000.0 in Q4 2020.
A 4-year average of $19.9 million and a median of $18.4 million in 2017 frame the typical range for Non-Current Debt.
Annual changes were most pronounced in 2016 — Non-Current Debt fell 24.1% — and 2017, when it soared 139.05%.
Tracing CRIS's Non-Current Debt over 4 years: stood at $14.9 million in 2016, then soared by 139.05% to $35.7 million in 2017, then dropped by 19.82% to $28.6 million in 2018, then plunged by 98.95% to $300000.0 in 2020.
The last three Non-Current Debt figures came in at $300000.0 (Q4 2020), $668000.0 (Q3 2020), and $445000.0 (Q2 2020), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	546.77 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	8.96 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	360.97 Mn
10	Curis	3.44 Mn	-2.18 Mn	-	-

Download Data